کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5928739 1167796 2013 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial
ترجمه فارسی عنوان
مبانی و طراحی واضح ضد انعقاد مطلوب از طریق آزمایش ژنتیک
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی

BackgroundCurrent dosing practices for warfarin are empiric and result in the need for frequent dose changes as the international normalized ratio gets too high or too low. As a result, patients are put at increased risk for thromboembolism, bleeding, and premature discontinuation of anticoagulation therapy. Prior research has identified clinical and genetic factors that can alter warfarin dose requirements, but few randomized clinical trials have examined the utility of using clinical and genetic information to improve anticoagulation control or clinical outcomes among a large, diverse group of patients initiating warfarin.MethodsThe COAG trial is a multicenter, double-blind, randomized trial comparing 2 approaches to guiding warfarin therapy initiation: initiation of warfarin therapy based on algorithms using clinical information plus an individual's genotype using genes known to influence warfarin response (“genotype-guided dosing”) versus only clinical information (“clinical-guided dosing”) (www.clinicaltrials.gov Identifier: NCT00839657).ResultsThe COAG trial design is described. The study hypothesis is that, among 1,022 enrolled patients, genotype-guided dosing relative to clinical-guided dosing during the initial dosing period will increase the percentage of time that patients spend in the therapeutic international normalized ratio range in the first 4 weeks of therapy.ConclusionThe COAG will determine if genetic information provides added benefit above and beyond clinical information alone.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: American Heart Journal - Volume 166, Issue 3, September 2013, Pages 435-441.e2
نویسندگان
, , , , , , , , , , , , , , , , , , , , , ,